ADVENZYMES

Advanced Enzyme Technologies share price & financials

Price
₹373.7
Market cap
₹3.4k Cr
Sector
Healthcare
Calls analysed
7
Latest concall · Q1 FY27 · call held 12 Aug 2026

Advanced Enzyme Technologies Limited Q1 FY27

Revenue 1,898 million +2%EBITDA 510 million −10%EBITDA Margin 27% PAT 386 million −5%

What went well

  • Revenue grew 2% YoY to INR 1,898 million despite challenges.
  • Bioprocessing segment reported strong 30% YoY revenue growth.
  • Specialized Manufacturing segment grew robustly by 41% YoY.

What to watch

  • EBITDA declined 10% YoY and 19% QoQ to INR 510 million, with margin compressing to 27% from 30% YoY.
  • PAT declined 5% YoY and 15% QoQ to INR 386 million.
Read the full call →

What Advanced Enzyme Technologies Limited does

Advanced Enzyme Technologies researches, develops and manufactures enzymes, probiotics and biocatalysts that replace chemical processes across human health, animal nutrition, food, brewing, textiles, leather and biofuel applications. It earns by selling proprietary enzyme and probiotic formulations to processors and consumer brands globally, and has grown inorganically through acquisitions such as evoxx Technologies (Germany), Scitech Specialities and a majority stake in JC Biotech. The company also runs a direct-to-consumer nutraceutical brand (Wellfa) through its US subsidiary Advanced Enzymes USA.

Segments

  • Human Nutrition
  • Animal Nutrition
  • Industrial Bio-Processing
  • Specialised Manufacturing
Manufacturing facilities
9
R&D centres
7
Countries with presence
45+
Proprietary enzyme/probiotic products
400+
Indigenous enzymes/probiotics developed
68+
Customers served
700+
Founded 1989Headquarters Thane, Maharashtra, IndiaEmployees 395 (FY2024-25 (as of March 3) Company website

Guidance record · Q1 FY27

what the last two calls moved 14 tracked 3 delivered 3 missed 8 open
  • Anti-inflammatory Products EU Approval went quiet said Q4 FY26 Promised: approval during this year (FY27) Q1 FY27: No specific update provided on the EU approval for anti-inflammatory products in the Q1 FY27 call.
  • FY27 Revenue Growth at risk said Q4 FY26 Promised: double-digit Q1 FY27: Q1 revenue grew only 2% YoY (approx. 7.4% adjusted for sales reversal), a soft start against the 'double-digit' target. Management reiterated confidence but the initial performance puts the goal at risk.
  • FY26 Revenue Growth delivered said Q4 FY25 Promised: mid-double-digit number Q4 FY26: FY26 total revenue grew 17% YoY, meeting the original 'mid-double-digit' guidance despite confusing language in Q3.

All 14 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue down 7.2%, net profit down 70.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue77 101 87 125 116 +51%96 −5%116 +33%116 −7%
EBITDA14 22 14 31 30 +114%23 +5%27 +93%30 −3%
Net profit9 15 11 74 22 +144%13 −13%22 +100%22 −70%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −13.8% 1Y

₹250₹300₹350₹400Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 13 Nov 2025Q3 FY26 — 4 Feb 2026Q4 FY26 — 12 May 2026Q1 FY27 — 12 Aug 2026

1Y: ₹340.3 on 10 Sept 2025 → ₹293.4. High ₹399.55 (11 May 2026), low ₹255.3 (30 Mar 2026).

How the price took the results

close before → close after

Q1 FY27
+1.1%
12 Aug
Q4 FY26
−7.4%
12 May
Q3 FY26
+2.2%
4 Feb
Q2 FY26
+3.2%
13 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue fell 2.2% a year over 3 years, FY23 to FY26. Operating margin narrowed to 24.5%.

Year endingFY23FY24FY25FY26
Revenue₹485 Cr₹365 Cr₹351 Cr₹453 Cr
Operating profit₹136 Cr₹106 Cr₹71 Cr₹111 Cr
Operating margin28.0%29.0%20.2%24.5%
Interest₹3 Cr₹0 Cr₹0 Cr₹0 Cr
Depreciation₹30 Cr₹12 Cr₹12 Cr₹12 Cr
Net profit₹90 Cr₹107 Cr₹102 Cr₹131 Cr
Net margin18.6%29.3%29.1%28.9%
Cash from operations₹50 Cr₹52 Cr₹63 Cr₹89 Cr
Free cash flow₹27 Cr₹31 Cr₹41 Cr₹44 Cr
ROCE15.0%28.0%20.0%24.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹22 Cr₹22 Cr₹22 Cr₹22 Cr₹22 Cr₹22 Cr
Reserves₹413 Cr₹458 Cr₹503 Cr₹558 Cr₹1.5k Cr₹687 Cr
Borrowings₹1 Cr₹2 Cr₹2 Cr₹2 Cr₹35 Cr₹2 Cr
Other liabilities₹53 Cr₹48 Cr₹48 Cr₹51 Cr₹173 Cr₹92 Cr
Total liabilities₹489 Cr₹530 Cr₹576 Cr₹633 Cr₹1.7k Cr₹804 Cr
Fixed assets₹131 Cr₹132 Cr₹143 Cr₹142 Cr₹683 Cr₹151 Cr
Capital work in progress₹7 Cr₹9 Cr₹11 Cr₹22 Cr₹31 Cr₹49 Cr
Investments₹184 Cr₹189 Cr₹201 Cr₹256 Cr₹529 Cr₹345 Cr
Other assets₹166 Cr₹200 Cr₹220 Cr₹213 Cr₹449 Cr₹259 Cr
Total assets₹489 Cr₹530 Cr₹576 Cr₹633 Cr₹1.7k Cr₹804 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, DIIs trimmed −3.68 pp while FIIs added +3.25 pp. The shareholder count shrank 6% to 63,599.

Promoters
43.3%
FIIs
26.7%
DIIs
4.8%
Public
25.3%

Since Jun 2025

  • DIIs −3.68 pp
  • FIIs +3.25 pp
  • Public +0.28 pp

How it drifted, 12 quarters

Over this window FIIs went from 22.3% to 26.7% — +4.4 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 45.9%, FIIs 22.3%, DIIs 6.5%, Public 25.3%.Dec '23: Promoters 43.6%, FIIs 22.5%, DIIs 7.0%, Public 26.9%.Mar '24: Promoters 43.5%, FIIs 23.0%, DIIs 7.6%, Public 25.9%.Jun '24: Promoters 43.0%, FIIs 12.0%, DIIs 8.1%, Public 36.9%.Sep '24: Promoters 43.0%, FIIs 12.6%, DIIs 8.0%, Public 36.4%.Dec '24: Promoters 42.9%, FIIs 12.6%, DIIs 8.2%, Public 36.3%.Mar '25: Promoters 43.1%, FIIs 11.9%, DIIs 8.2%, Public 36.8%.Jun '25: Promoters 43.1%, FIIs 23.4%, DIIs 8.4%, Public 25.0%.Sep '25: Promoters 43.1%, FIIs 25.4%, DIIs 6.4%, Public 25.1%.Dec '25: Promoters 43.0%, FIIs 25.9%, DIIs 5.5%, Public 25.6%.Mar '26: Promoters 43.3%, FIIs 25.5%, DIIs 5.4%, Public 25.9%.Jun '26: Promoters 43.3%, FIIs 26.7%, DIIs 4.8%, Public 25.3%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Advanced Enzyme Technologies Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Vasant Rathi 26.68%unchanged
Orbimed Asia III Mauritius FVCI Limited FPI fund12.06%unchanged
Nalanda India Equity Fund Limited FPI fund8.45%unchanged
Vasant and Prabha Rathi Generation Trust 6.70%unchanged
Polunin Emerging Markets Small Cap Fund, LLC FPI fund2.46%+1.14 pp
Rasika Vasant Rathi 2.38%unchanged
Rachana Vasant Rathi 2.36%unchanged
Reshma Namita Rathi 2.36%unchanged
Clarus Capital I VC / PE2.28%−0.47 pp
Marval Guru Fund FPI fund1.79%unchanged
Pradip Bhailal Shah 1.66%unchanged
Mukund Madhusudan Kabra 1.63%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

All earnings calls (7)

Read the Q1 FY27 call →

Learn to analyse Advanced Enzyme Technologies Limited

Guides on how to read this kind of business and the numbers that matter.